Phibro Animal Health Corp: Form 10-Q for the period ended Dec 31, 2024
Filed with the SEC on Feb 5, 2025 and accepted by EDGAR at Feb 5, 2025, 21:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-10-01 to 2024-12-31 | $309.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-07-01 to 2024-12-31 | $569.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-10-01 to 2024-12-31 | $207.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2024-07-01 to 2024-12-31 | $384.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-10-01 to 2024-12-31 | $101.9m | us-gaap:GrossProfit |
| Gross profit | 6 months2024-07-01 to 2024-12-31 | $185.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2024-10-01 to 2024-12-31 | $76.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-07-01 to 2024-12-31 | $142.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-10-01 to 2024-12-31 | $25.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-07-01 to 2024-12-31 | $43.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-10-01 to 2024-12-31 | $9.8m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2024-07-01 to 2024-12-31 | $18.5m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-10-01 to 2024-12-31 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-07-01 to 2024-12-31 | $4.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-10-01 to 2024-12-31 | $3.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-07-01 to 2024-12-31 | $10.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-10-01 to 2024-12-31 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-07-01 to 2024-12-31 | $0.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-10-01 to 2024-12-31 | $0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-07-01 to 2024-12-31 | $0.25 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-10-01 to 2024-12-31 | 40,715,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-07-01 to 2024-12-31 | 40,649,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-07-01 to 2024-12-31 | $15.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-07-01 to 2024-12-31 | $17.4m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 6 months2024-07-01 to 2024-12-31 | $9.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2024-12-31 | $67.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $746.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $1.29bn | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $233.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $1.04bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-12-31 | $622.9m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-12-31 | $16.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-12-31 | $246.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-25-000659. Last ingested by Listed: Oct 24, 2026, 15:03 ET. Listed shows no prices and gives no investment advice.